Please login to the form below

Not currently logged in
Email:
Password:

trastuzumab

This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.

AZ strengthens Daiichi Sankyo partnership with new ADC deal

AZ strengthens Daiichi Sankyo partnership with new ADC deal

acalabrutinib) and its recently approved, Daiichi-partnered HER2-targeting ADC, Enhertu (trastuzumab deruxtecan).

Latest news

More from news
Approximately 14 fully matching, plus 166 partially matching documents found.

Latest Intelligence

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    The rise of the monoclonal antibody. Trastuzumab was the first monoclonal antibody tested in clinical trials, designed to inhibit human epidermal growth factor receptor 2 (HER2) which, when activated, promotes breast ... Trastuzumab successfully reduced

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2.

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... 4. Daiichi Sankyo. The fourth company on our list – Daiichi Sankyo – has something in common with the first.Our

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .

  • Deal Watch October 2016 Deal Watch October 2016

    Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics